Schedule 13G ownership disclosure

Vistagen Therapeutics Inc

Common Stock, par value $0.001 per share · CUSIP: 92840H400

Event date: 2024-12-31

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • BIOTECHNOLOGY VALUE FUND L P

    Shares: 1,589,495.00 · Class: 5.4%

  • BVF I GP LLC

    Shares: 1,589,495.00 · Class: 5.4%

  • BIOTECHNOLOGY VALUE FUND II LP

    Shares: 1,289,734.00 · Class: 4.4%

  • BVF II GP LLC

    Shares: 1,289,734.00 · Class: 4.4%

  • Biotechnology Value Trading Fund OS LP

    Shares: 158,606.00 · Class: 0.6%

  • BVF Partners OS Ltd.

    Shares: 158,606.00 · Class: 0.6%

  • BVF GP HOLDINGS LLC

    Shares: 2,879,229.00 · Class: 9.4%

  • BVF PARTNERS L P/IL

    Shares: 3,084,324.00 · Class: 9.97%

  • BVF INC/IL

    Shares: 3,084,324.00 · Class: 9.97%

  • LAMPERT MARK N

    Shares: 3,084,324.00 · Class: 9.97%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000921895-25-000500
Form type
SCHEDULE 13G/A
Filer
BIOTECHNOLOGY VALUE FUND L P
CIK
CIK 918923
Filed
Feb 14, 2025
Reporting period
Dec 31, 2024
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub